On June 2, 2025, Xilio Therapeutics, Inc. announced an underwritten public offering for 66.68 million pre-funded and common stock warrants, expecting to raise approximately $46.6 million. The company aims to fund operations through at least Q3 2026, relying on these proceeds alongside existing cash.